FDA accepts BeiGene’s sNDA for follicular lymphoma therapy
2023-07-13
孤儿药引进/卖出临床结果临床2期快速通道
Preview
来源: Pharmaceutical Technology
BeiGene haematology chief medical officer Mehrdad Mobasher noted that Brukinsa is the first Bruton’s tyrosine kinase inhibitorBruton’s tyrosine kinase inhibitor to demonstrate efficacy in follicular lymphoma. Credit: BeiGene / Business Wire.
The US Food and Drug Administration (FDA) has accepted for review BeiGene’s supplemental new drug application (sNDA) for Brukinsa (zanubrutinib) plus obinutuzumab to treat relapsed or refractory (R/R) follicular lymphoma (FL).
The treatment is indicated for use in adult R/R FL patients, following a minimum of two previous lines of therapy.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Naratuximab Emtansine in Follicular Lymphoma GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Atezolizumab in Follicular Lymphoma GlobalData
View allCompanies IntelligenceBeiGene LtdRosewood CorpView all
A decision on the approval for the treatment is expected in the first quarter of 2024.
Brukinsa is a small molecule Bruton’s tyrosine kinase (BTK) inhibitorBruton’s tyrosine kinase (BTK) inhibitor that received fast track and orphan drug designation for R/R FL treatment.
The filing is based on findings from the Phase II ROSEWOOD clinical trial in 217 R/R non-Hodgkin FL patients, who had previously received treatment.
Safety data from the trial were in line with those from prior studies of both therapies.
Longer-term trial findings also showed that the efficacy benefit of Brukinsa plus obinutuzumab continued at a median follow-up of 20.2 months.
BeiGene haematology chief medical officer Mehrdad Mobasher stated: “Follicular lymphoma is the most common slow-growing non-Hodgkin lymphoma, but there are limited treatment options for patients whose condition has progressed after two lines of therapy.
“We are therefore pleased that Brukinsa is the first Bruton’s tyrosine kinase inhibitorBruton’s tyrosine kinase inhibitor to demonstrate efficacy in follicular lymphoma and plan to continue worldwide regulatory submissions based on the ROSEWOOD results.”
The submissions for Brukinsa in the same indication are under review in China, Canada, Switzerland, the European Union and the UK.
The latest development comes after the company entered a licence agreement for DualityBio’s antibody-drug conjugate therapy to treat certain solid tumours.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。